Lyon-France, March 15, 2011, Adocia, a privately-held biotechnology company specialized inregenerative medicine and in the treatment of chronic diseases, announced positive
results from its phase I clinical study evaluating the safety and clinical utility of HinsBet®, its fast-acting human insulin product for the treatment of diabetes. This project benefits from FEDER support.
The trial compared the product candidate, HinsBet®, to NovoLog® (Novo Nordisk), a fast-acting insulin analog, and Actrapid® (Novo Nordisk), a regular human insulin. It was a double blind study involving 12 healthy volunteers. The pharmacokinetic and pharmacodynamic profiles were obtained using the glucose clamp technique.
On the primary endpoint of safety, HinsBet® showed identical results to the commercial products tested, giving excellent local tolerance and absence of pain at the site of injection...
[...]
...About Adocia SAS
Adocia (Lyon, France) is a privately held French biotechnology company in specialized regenerative medicine and in the treatment of chronic diseases. Adocia is developing innovative protein formulations based on its proprietary technology, BioChaperone®. These include new formulations of BMPs (bone morphogenic proteins) for bone repair and other indications. Adocia is also engaged in two collaborative programs on the formulation of monoclonal antibodies using its BioChaperone® platform with two biopharma companies, and it has three collaborations with medtech companies... [PDF] Adocia's Press Release -
